Building new therapies atom by atom
ABOUT US
Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. We aim to create products that will transform health outcomes for millions of people with cancer and other challenging diseases.
OUR SCIENCE
Our lead candidate NBTXR3 is a potential first-in-class radioenhancer with therapeutic applications across a range of solid tumors. NBTXR3 is designed to increase the dose of radiotherapy that is absorbed and deposited into tumor cells without increasing the dose in surrounding healthy tissues, thereby destroying the target tumor and priming the immune response attack on metastatic tumors.
OUR PIPELINE
We believe that NBTXR3 offers broad potential to help patients fight cancer. To realize this potential, Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the co-development and commercialization of the first-in-class radioenhancer. The development plan is initially focused on cancers of the head, neck, and lungs, aiming to help vulnerable patient populations with limited treatment options and provide the clinical foundation for expansion across any indication and/or therapeutic combination, including radiotherapy.
PARTNERS & COLLABORATIONS
We pride ourselves in collaborating with institutions that share our vision of developing safer, more effective therapies for people with cancer and other challenging diseases.
Patients
Our physics-based approach has the potential to overcome many of the challenges associated with traditional cancer therapy and may lead to better patient outcomes. Learn more about our clinical trials, access resources, and find advocacy partners.
SCIENTIFIC Publications
Delve deeper into the research behind our transformative science.
Interested in joining a highly collaborative team that is pushing the potential of cutting-edge science and committed to making a difference for humanity? We would love to hear from you.